1.60 I-PREDICT, Flawed Phase I Trials, & the Cost of Drugs with Dr. Daniel Hartung
We revisit I-PREDICT, discuss the "Imputability o…
Plenary Session - inactive due to federal service · Plenary Session - inactive due to federal service
May 9, 20191h 20mExplicit
Audio is streamed directly from the publisher (feeds.soundcloud.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
We revisit I-PREDICT, discuss the "Imputability of Adverse Events to Anticancer Drugs" (a letter published recently in the New England Journal of Medicine), and interview Dr. Daniel Hartung of Oregon State University's College of Pharmacy on his vast knowledge of the cost of drugs, specifically addressing Acthar gel and multiple sclerosis drugs.
Imputability of Adverse Events: doi.org/10.1056/NEJMc1900053
Back us on Patreon! www.patreon.com/plenarysession
Topics
medicineoncologyhealthpolicy